TY - JOUR
T1 - Long-Term Effect of Macrolides on Helicobacter pylori Eradication
T2 - Data From the European Registry on Helicobacter pylori Management (Hp-EuReg)
AU - the Hp-EuReg investigators
AU - Nyssen, Olga P.
AU - Ortega, Guillermo J.
AU - Jonaitis, Laimas
AU - Pérez-Aísa, Ángeles
AU - Tepes, Bojan
AU - Lucendo, Alfredo J.
AU - Tejedor-Tejada, Javier
AU - Bumane, Renate
AU - Garre, Ana
AU - Huguet, Jose M.
AU - Perona, Monica
AU - Núñez, Óscar
AU - Pabón-Carrasco, Manuel
AU - Castro-Fernández, Manuel
AU - Areia, Miguel
AU - Barrio, Jesús
AU - Loro, Antonio Moreno
AU - Butler, Thomas J.
AU - Marcos, María Soledad
AU - Keco-Huerga, Alma
AU - Cajal, Manuel Domínguez
AU - Denkovski, Maja
AU - Pavoni, Matteo
AU - Buzás, György Miklós
AU - Lerang, Frode
AU - Losurdo, Giuseppe
AU - Wolfe García, Pablo M.
AU - Phull, Perminder S.
AU - Martínez-Domínguez, Samuel J.
AU - Kupcinskas, Juozas
AU - Leja, Mārcis
AU - Marcos-Pinto, Ricardo
AU - Smith, Sinead M.
AU - Gasbarrini, Antonio
AU - Papp, Veronika
AU - Rodríguez, Blas José Gómez
AU - Alonso, Mónica Sánchez
AU - Villarroya, Ramón Pajares
AU - Mejide, Pilar Pazo
AU - Jiménez-Moreno, Manuel
AU - Pascual-Mato, Marta
AU - Bravo-Pache, Concepción
AU - Montes, Milagrosa
AU - Cano-Català, Anna
AU - Parra, Pablo
AU - Moreira, Leticia
AU - Mégraud, Francis
AU - O’Morain, Colm
AU - Bujanda, Luis
AU - Gisbert, Javier P.
N1 - Publisher Copyright:
© 2026 The Author(s). Helicobacter published by John Wiley & Sons Ltd.
PY - 2026/1/1
Y1 - 2026/1/1
N2 - Background and Aims: Previous antibiotic use influences Helicobacter pylori antibiotic resistance. This study evaluated how prior population-level macrolide (especially clarithromycin) use affects H. pylori eradication success in naïve patients. Methods: Retrospective, multicenter, ecological study. Multivariate logistic regression was performed with modified intention-to-treat effectiveness as the main outcome. Key variables included first-line clarithromycin-based treatments, therapy duration (7, 10, 14 days), proton pump inhibitor dose (low, standard, high), compliance (> 90%), and clarithromycin consumption (defined daily doses/1000 inhabitants/day, from the European Surveillance of Antimicrobial Consumption Network). Nested hierarchical models incorporated macrolide consumption, matched by year and country, and assessed the interaction between consumption and first-line empirical treatments from the European Registry on H. pylori Management (Hp-EuReg). Results: The study included 27,549 naïve patients from 23 countries with macrolide consumption data from 2013 to 2022. Higher macrolide consumption, within 0 to 8 years before treatment, was associated with reduced treatment effectiveness. The eradication rate consistently decreased as macrolide consumption increased, particularly within the previous 4 years. The efficacy of triple-clarithromycin-metronidazole, triple-clarithromycin-amoxicillin, and some bismuth-quadruple therapies containing clarithromycin decreased with higher macrolide consumption. At the country level, higher population consumption of clarithromycin 2 years before treatment was associated with a decrease in eradication rates from 93% to 82%. Conclusion: Higher macrolide consumption in the general population negatively impacts the effectiveness of first-line H. pylori regimens. These findings support that clarithromycin should only be administered as a susceptibility-based therapy, with the strongest negative impact of prior population-level exposure observed within 5 years and diminishing thereafter. ClincialTrials.gov number, NCT02328131.
AB - Background and Aims: Previous antibiotic use influences Helicobacter pylori antibiotic resistance. This study evaluated how prior population-level macrolide (especially clarithromycin) use affects H. pylori eradication success in naïve patients. Methods: Retrospective, multicenter, ecological study. Multivariate logistic regression was performed with modified intention-to-treat effectiveness as the main outcome. Key variables included first-line clarithromycin-based treatments, therapy duration (7, 10, 14 days), proton pump inhibitor dose (low, standard, high), compliance (> 90%), and clarithromycin consumption (defined daily doses/1000 inhabitants/day, from the European Surveillance of Antimicrobial Consumption Network). Nested hierarchical models incorporated macrolide consumption, matched by year and country, and assessed the interaction between consumption and first-line empirical treatments from the European Registry on H. pylori Management (Hp-EuReg). Results: The study included 27,549 naïve patients from 23 countries with macrolide consumption data from 2013 to 2022. Higher macrolide consumption, within 0 to 8 years before treatment, was associated with reduced treatment effectiveness. The eradication rate consistently decreased as macrolide consumption increased, particularly within the previous 4 years. The efficacy of triple-clarithromycin-metronidazole, triple-clarithromycin-amoxicillin, and some bismuth-quadruple therapies containing clarithromycin decreased with higher macrolide consumption. At the country level, higher population consumption of clarithromycin 2 years before treatment was associated with a decrease in eradication rates from 93% to 82%. Conclusion: Higher macrolide consumption in the general population negatively impacts the effectiveness of first-line H. pylori regimens. These findings support that clarithromycin should only be administered as a susceptibility-based therapy, with the strongest negative impact of prior population-level exposure observed within 5 years and diminishing thereafter. ClincialTrials.gov number, NCT02328131.
KW - antibiotic consumption
KW - clarithromycin
KW - eradication treatment
KW - H. pylori
KW - macrolide
KW - resistance
UR - https://www.scopus.com/pages/publications/105029606428
U2 - 10.1111/hel.70107
DO - 10.1111/hel.70107
M3 - Article
C2 - 41656747
AN - SCOPUS:105029606428
SN - 1083-4389
VL - 31
JO - Helicobacter
JF - Helicobacter
IS - 1
M1 - e70107
ER -